Phase II study of irinotecan+5FU/FA for patients with previously treated advanced gastric cancer.

被引：0
|
作者：
Peeters, M
Van Laethem, JL
Baert, F
Canon, JL
De Grève, J
Kalantari, H
Dhont, P
Van Cutsem, E
机构：
[1] State Univ Ghent Hosp, B-9000 Ghent, Belgium
[2] Erasme Univ Hosp, B-1070 Brussels, Belgium
[3] H Hart Hosp, Roeselare, Belgium
[4] Clin Notre Dame, Charleroi, Belgium
[5] Univ Brussels, Acad Ziekenhuis, Ghent, Belgium
[6] Ctr Hosp Peltzer La Tourelle, Verviers, Belgium
[7] Aventis Pharma, Brussels, Belgium
[8] Katholieke Univ Leuven, Hosp Gasthuisberg, Louvain, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4076
引用
收藏
页码：332S / 332S
页数：1
相关论文
共 50 条
  • [31] Phase II study of capecitabine, irinotecan, and celecoxib in advanced colorectal cancer.
    El-Rayes, BF
    Shields, AF
    Vaishampayan, U
    Heilbrun, L
    Bekaii-Saab, T
    Zalupski, MM
    Philip, PA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 310S - 310S
  • [32] Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer
    Baek, J. H.
    Kim, J. G.
    Jeon, S. B.
    Chae, Y. S.
    Kim, D. H.
    Sohn, S. K.
    Lee, K. B.
    Choi, Y. J.
    Shin, H. J.
    Chung, J. S.
    Cho, G. J.
    Jung, H. Y.
    Yu, W.
    BRITISH JOURNAL OF CANCER, 2006, 94 (10) : 1407 - 1411
  • [33] Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer
    J H Baek
    J G Kim
    S B Jeon
    Y S Chae
    D H Kim
    S K Sohn
    K B Lee
    Y J Choi
    H J Shin
    J S Chung
    G J Cho
    H Y Jung
    W Yu
    British Journal of Cancer, 2006, 94 : 1407 - 1411
  • [34] A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer
    Bando, Hideaki
    Shimodaira, Hideki
    Fujitani, Kazumasa
    Takashima, Atsuo
    Yamaguchi, Kensei
    Nakayama, Norisuke
    Takahashi, Takehiro
    Oki, Eiji
    Azuma, Mizutomo
    Nishina, Tomohiro
    Hironaka, Shuichi
    Komatsu, Yoshito
    Shitara, Kohei
    EUROPEAN JOURNAL OF CANCER, 2018, 91 : 86 - 91
  • [35] A phase 2, open-label study of amivantamab in patients with previously treated advanced or metastatic gastric or esophageal cancer.
    Kotani, Daisuke
    Yamaguchi, Kensei
    Kato, Ken
    Hara, Hiroki
    Miura, Akinori
    Satoh, Taroh
    Komine, Keigo
    Kunisaki, Chikara
    Yabusaki, Hiroshi
    Hagiwara, Akiko
    Suzuki, Noriko
    Toyoizumi, Kiichiro
    Curtin, Joshua C.
    Chowdhury, Sanjib
    Knoblauch, Roland Elmar
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 363 - 363
  • [36] Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study
    Suenaga, Mitsukuni
    Mizunuma, Nobuyuki
    Matsusaka, Satoshi
    Shinozaki, Eiji
    Ozaka, Masato
    Ogura, Mariko
    Yamaguchi, Toshiharu
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 3099 - 3108
  • [37] Phase II study of paclitaxel, cisplatin, and 5-FU combination chemotherapy in patients with advanced gastric cancer
    Cho, S.
    Shim, H.
    Lee, S.
    Ahn, J.
    Yang, D.
    Kim, Y.
    Park, C.
    Lee, J.
    Chung, I.
    Kim, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [38] Phase II study of trastuzumab with irinotecan in HER2-positive gastric cancer previously treated with trastuzumab
    Hatanaka, Kazuteru
    Kawamoto, Yasuyuki
    Yuki, Satoshi
    Meguro, Takashi
    Uebayashi, Minoru
    Abe, Masakazu
    Nakamura, Michio
    Okuda, Hiroyuki
    Sakata, Yuh
    Komatsu, Yoshito
    ANNALS OF ONCOLOGY, 2017, 28
  • [39] A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma
    Blanke, CD
    Haller, DG
    Benson, AB
    Rothenberg, ML
    Berlin, J
    Mori, M
    Hsieh, YC
    Miller, LL
    ANNALS OF ONCOLOGY, 2001, 12 (11) : 1575 - 1580
  • [40] Phase I/II-study with 5-FU, leucovorin, oxaliplatin (FLO) and mitomycin C (MMC; FLOM) in patients (PTS) with previously treated advanced gastric cancer (AGC)
    Atmaca, Akin
    Al-Batran, Salah-Eddin
    Kerber, Anne
    Schmidt, Sebastian
    Kolassa, Yvonne
    Neumann, Antje
    Hartmann, Joerg Thomas
    Weidmann, Eckhart
    Jaeger, Elke
    ANNALS OF ONCOLOGY, 2006, 17 : 316 - 316
12345